[Skip to Content]

Claim CME

Cardiology

Management of Heart Failure

To identify the key insights or developments described in this article

1 Credit CME

JAMA

Published Online: September 15, 2022

JAMA Clinical Guidelines Synopsis

Article Information and Disclosures

Mark N. Belkin, MD¹;

Adam S. Cifu, MD¹;

Sean Pinney, MD¹

Author Affiliations

¹University of Chicago, Chicago, Illinois

Read article on JAMA Network

Read Article Claim CME

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Adam S. Cifu, MD, University of Chicago, 5841 S Maryland Ave, MC 3051, Chicago, IL 60637 (adamcifu@uchicago.edu).

Published Online: September 15, 2022. doi:10.1001/jama.2022.16667

Correction: This article was corrected on January 17, 2023, to fix an incorrect term.

Conflict of Interest Disclosures: Dr Pinney reported receipt of personal fees from Abbott, CareDx, Medtronic, TransMedics, Valgen Medtech, Ancora Heart, and ADS and nonfinancial support from Procyrion. No other disclosures were reported.

References

Packer M , Anker SD , Butler J , et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. PubMed Google Scholar Crossref

Zannad F , Ferreira JP , Pocock SJ , et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction. Lancet. 2020;396(10254):819-829. doi:10.1016/S0140-6736(20)31824-9 PubMed Google Scholar Crossref

Anker SD , Butler J , Filippatos G , et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 PubMed Google Scholar Crossref

McMurray JJ , Packer M , Desai AS , et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077 PubMed Google Scholar Crossref

Heidenreich PA , Bozkurt B , Aguilar D , et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012 PubMed Google Scholar Crossref

McMurray JJV , Solomon SD , Inzucchi SE , et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303 PubMed Google Scholar Crossref

Halliday BP , Wassall R , Lota AS , et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF). Lancet. 2019;393(10166):61-73. PubMed Google Scholar Crossref

Bhagat AA , Greene SJ , Vaduganathan M , et al. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail. 2019;7(1):1-12. doi:10.1016/j.jchf.2018.06.011 PubMed Google Scholar Crossref

Rao VN , Murray E , Butler J , et al. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;78(20):2004-2012. PubMed Google Scholar Crossref

Yancy CW , Jessup M , Bozkurt B , et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776-803. doi:10.1016/j.jacc.2017.04.025 PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 CME points in the American Board of Surgery’s (ABS) Continuing Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.